Clinical performance with the levitronix centrimag short-term ventricular assist device
Clinical performance with the levitronix centrimag short-term ventricular assist device
复制标题
DOI：
10.1016/j.healun.2005.08.019
复制
发表时间：
2006-02-01
影响因子：
8.9
通讯作者：
Khaghani, A
中科院分区：
文献类型：
--
作者：
De Robertis, F;Birks, EJ;Khaghani, A
背景：Levitronix心室辅助装置（VAD）是一种用于体外支持的离心泵，无需机械轴承或密封。转子是磁悬浮的，因此在没有摩擦或磨损的情况下实现旋转，这似乎可以最大限度地减少血液损伤和机械故障。本研究的目的是报告我们使用Levitronix Centrimag设备的早期结果。方法：2003年6月至2005年4月，我院18例患者（患者）使用Levitronix。男性14人。平均年龄40.3±18.3岁（8 ~ 64岁）。植入时支持指征：A组12例为开心术后心源性休克，B组6例为决定是否需要长期心室支持。结果：所有患者的平均支持时间为14.2±15.2天（1 ~ 64天）。手术（30天）死亡率为50%（9例）。A组6例，b组3例。总的来说，6例（33%）出院回家，目前生活良好（平均随访13个月，范围5至17个月）。出血需再次手术8例（44%），脑血栓栓塞1例，肺栓塞1例。没有设备故障。结论：Levitronix功能良好，并被证明对预后极差的患者是有用的，以前认为不适合长期辅助装置。该装置在技术上易于植入和管理。没有设备功能障碍，并发症是可接受的或与其他设备一致。存活到移植或最终手术（VAD或移植）是令人鼓舞的。
Background: The Levitronix ventricular assist device (VAD) is a centrifugal pump designed for extracorporeal support and that operates without mechanical bearings or seals. The rotor is magnetically levitated so that rotation is achieved without friction or wear, which seems to minimize blood trauma and mechanical failure. The aim of this study is to report our early results with the Levitronix Centrimag device.Methods: Between June 2003 and April 2005, 18 patients (pts) were supported using the Levitronix at our institution. Fourteen were male. Mean age was 40.3 +/- 18.3 (range 8 to 64) years. Indications for support at implantation were: post-cardiotomy cardiogenic shock in 12 cases (Group A), and bridge to decision regarding long-term ventricular support in 6 cases (Group B).Results: Mean support time was 14.2 +/- 15.2 days for all patients (range 1 to 64 days). Operative (30-day) mortality was 50% (9 pts). Six pts were in Group A and 3 pts were in Group B. Overall, 6 pts (33%) were discharged home and are presently alive and well (mean follow-up 13 months, range 5 to 17 months). Bleeding requiring re-operation occurred in 8 cases (44%), cerebral thromboembolism in I and pulmonary embolism in 1. There were no device failures.Conclusions: The Levitronix functioned well and proved to be useful in patients with extremely poor prognosis previously considered non-suitable for a long-term assist device. The device was technically easy to implant and manage. There was no device dysfunction and complications were acceptable or consistent with other devices. Survival to explant or a definitive procedure (VAD or transplantation) was encouraging.